Quantification and Structure Elucidation of in Vivo Bevacizumab Modification in Rabbit Vitreous Humor after Intravitreal Injection

被引:7
作者
Chu, Kai On [1 ,2 ]
Liu, David Ta Li [1 ]
Chan, Kwok Ping [1 ]
Yang, Ya Ping [1 ]
Yam, Gary Hin Fai [1 ]
Rogers, Michael S. [2 ,3 ]
Pang, Chi Pui [1 ]
机构
[1] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Obstet & Gynaecol, Kowloon, Hong Kong, Peoples R China
[3] Hong Kong Surg Specialists, Hong Kong, Hong Kong, Peoples R China
关键词
quantification; characterization; bevacizumab; immunoglobulin; vitreous humor; FLIGHT MASS-SPECTROMETRY; ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; RETINAL VEIN OCCLUSION; MONOCLONAL-ANTIBODY; AFFINITY-CHROMATOGRAPHY; AVASTIN THERAPY; GLYCOSYLATION; ELECTROSPRAY; PHARMACOKINETICS;
D O I
10.1021/mp3005403
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Off-label and intravitreal use of bevacizumab, a recombinant immunoglobulin against VEGF, has been practiced widely for ophthalmic treatments. However, longitudinal data of its intravitreal status is unavailable due to a lack of reliable methods for bevacizumab determination. Thus its pharmacokinetics and pharmacodynamics are uncertain. We developed and validated a high performance liquid chromatographic method to determine bevacizumab in vitreous humor and utilized a novel strategy to assess in vivo temporal binding changes by affinity chromatography. Mass spectrometry and tandem mass spectrometry detection were used for structural evaluation. The coefficient of variation (CV) for intrabatch imprecision varied from 0.5 to 14.3% and for interbatch imprecision from 1.9 to 11.6%. The linearity was over 0.9982, lower limit of quantification 1.95 mu g, recoveries over 95%, and accuracy between 90 and 112% over the range of 1.95-250 mu g of bevacizumab in 100 mu L of vitreous humor. Blank vitreous humor showed no interference peak. It was stable at room temperature for 5 h. Bevacizumab elimination in the vitreous followed first order kinetics with half-life as 5.7 days and elimination rate as 0.1221 day(-1). Peptide mapping and tandem mass spectrometry revealed structural modifications of the in vivo bevacizumab mainly on the heavy chain in both variable and constant regions 7 days after intravitreal injection. Minor changes were also discovered on the light chain. Affinity chromatography showed significant affinity changes in samples 21 days after intravitreal injection. The changes were consistent with structural modifications as found in endothelial cell migration assays results. In conclusion, we have established a robust chromatographic method for determination of bevacizumab and strategies with affinity chromatography and molecular mass detection that revealed bevacizumab structural and possible functional changes in vitreous.
引用
收藏
页码:3422 / 3433
页数:12
相关论文
共 31 条
[1]   A platform for high-throughput molecular characterization of recombinant monoclonal antibodies [J].
Bailey, MJ ;
Hooker, AD ;
Adams, CS ;
Zhang, SH ;
James, DC .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 826 (1-2) :177-187
[2]   Pharmacokinetics of intravitreal bevackumab (avastin) [J].
Bakri, Sophie J. ;
Snyder, Melissa R. ;
Reid, Joel M. ;
Pulido, Jose S. ;
Singh, Ravinder J. .
OPHTHALMOLOGY, 2007, 114 (05) :855-859
[3]   Six-month stability of bevacizumab (avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing [J].
Bakri, Sophie J. ;
Snyder, Melissa R. ;
Pulido, Jose S. ;
McCannel, Colin A. ;
Weiss, William T. ;
Singh, Ravinder J. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (05) :519-522
[4]   Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients [J].
Beer, Paul M. ;
Wong, Susan J. ;
Hammad, Amjad M. ;
Falk, Naomi S. ;
O'Malley, Martin R. ;
Khan, Samira .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (08) :871-876
[5]   Validation of a peptide mapping method for a therapeutic monoclonal antibody: what could we possibly learn about a method we have run 100 times? [J].
Bongers, J ;
Cummings, JJ ;
Ebert, MB ;
Federici, MM ;
Gledhill, L ;
Gulati, D ;
Hilliard, GM ;
Jones, BH ;
Lee, KR ;
Mozdzanowski, J ;
Naimoli, M ;
Burman, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 21 (06) :1099-1128
[6]   Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide) [J].
Byeon, Suk Ho ;
Kwon, Oh W. ;
Song, Ji Hun ;
Kim, Sung Eun ;
Park, Yong Sik .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (01) :35-42
[7]   Frontal affinity chromatography in characterizing immobilized receptors [J].
Calleri, E. ;
Temporini, C. ;
Massolini, G. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 54 (05) :911-925
[8]   In Vitro Screening for Angiostatic Potential of Herbal Chemicals [J].
Cao, Liming ;
Liu, Huanming ;
Lam, Dennis Shun-Chiu ;
Yam, Gary Hin-Fai ;
Pang, Chi-Pui .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (12) :6658-6664
[9]   Integrated approach for manual evaluation of peptides identified by searching protein sequence databases with tandem mass spectra [J].
Chen, Y ;
Kwon, SW ;
Kim, SC ;
Zhao, YM .
JOURNAL OF PROTEOME RESEARCH, 2005, 4 (03) :998-1005
[10]   Improving mass accuracy of high performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry of intact antibodies [J].
Gadgil, Himanshu S. ;
Pipes, Gary D. ;
Dillon, Thomas M. ;
Treuheit, Michael J. ;
Bondarenko, Pavel V. .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2006, 17 (06) :867-872